SUBSCRIBE
SUBSCRIBE

GLP-1

Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Genetown
Boston ‘Unicorn’ Intarcia Banks a Whopping $215 Million to Support Diabetes Drug Pump
September 16, 2016
 · 
3 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Biotech Beach
2 High-Risk Biotechs Ready to Rock—Maybe
August 30, 2016
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Merrion Pharma Looks to Wind Up Operations, Announces Liquidation Plans
August 23, 2016
 · 
2 min read
With Hopes of Bolstering Sanofi’s Sagging Diabetes Sector, Announces FDA Approval of Adlyxin in U.S.
FDA
With Hopes of Bolstering Sanofi’s Sagging Diabetes Sector, Announces FDA Approval of Adlyxin in U.S.
July 28, 2016
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
Novo Nordisk A/S Investors Disappointed as Top Selling Drug Victoza Didn’t Do as Well as Expected
June 14, 2016
 · 
2 min read
Job Trends
Intarcia to Move HQ Next Month, Plans to Double Workforce By End of 2017
June 14, 2016
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Job Trends
As Part of Worldwide Expansion, Novo Nordisk A/S Spends 100 Million Euros to Build in France
April 21, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Business
Eli Lilly Abandons Development of Transition Therapeutics’ Diabetes Candidate TT401
April 18, 2016
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Business
Bay Area Startup Rani Therapeutics Tops $70 Million in Funding With Heavy Hitters like AstraZeneca PLC, Novartis AG and Google
February 24, 2016
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Policy
Sanofi Pays $20 Million Milestone and Redeems Priority Review Voucher for Zealand Pharma ’s LixiLan
December 23, 2015
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
Eccogene Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China
February 11, 2026
 · 
4 min read
Press Releases
Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide
February 10, 2026
 · 
8 min read
Press Releases
Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
February 4, 2026
 · 
9 min read
Press Releases
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
February 3, 2026
 · 
6 min read
Press Releases
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
February 1, 2026
 · 
8 min read
Press Releases
LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
January 30, 2026
 · 
5 min read
Press Releases
BetterWay Launches GLP-1 Blood Testing Panel at Retail Locations in Austin and Temple
January 30, 2026
 · 
2 min read
Press Releases
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation
January 29, 2026
 · 
8 min read
Press Releases
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
January 28, 2026
 · 
3 min read
Press Releases
Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
January 28, 2026
 · 
3 min read
Press Releases
Baseline Therapeutics Launches to Advance GLP-1RA Phase 3 Program in Alcohol Use Disorder
January 28, 2026
 · 
3 min read
Press Releases
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
January 27, 2026
 · 
4 min read
Press Releases
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
January 27, 2026
 · 
6 min read
Press Releases
Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
January 26, 2026
 · 
4 min read
Press Releases
CORXEL Announces $287 million Series D1 Financing to Further Advance Its Cardiometabolic Pipeline including Oral Small Molecule GLP-1 Receptor Agonist
January 23, 2026
 · 
3 min read
Press Releases
Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
January 20, 2026
 · 
4 min read
Press Releases
RO ANNOUNCES RESEARCH COLLABORATION TO BETTER UNDERSTAND AND IMPROVE THE REAL-WORLD PATIENT EXPERIENCE WITH GLP-1S
January 13, 2026
 · 
2 min read
Press Releases
Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)
January 13, 2026
 · 
6 min read
Press Releases
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
January 12, 2026
 · 
8 min read
Press Releases
LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform
January 9, 2026
 · 
6 min read
Load More